EPL Ltd
NSE: EPL BSE: 500135Pharma
EPL Limited (formerly known as Essel Propack Limited),is the largest specialty packaging global company, manufacturing laminated plastic tubes catering to the Beauty & Cosmetics, Pharma & Health, Food, Oral and Home.
₹214
52W: ₹176 — ₹254
PE 21.6 · Book ₹36.9 · +480% vs bookMarket Cap₹6,850 Cr
Stock P/E21.6Price to Earnings
ROCE22.9%Return on Capital
ROE28.6%Return on Equity
Div. Yield2.37%Face Value ₹2
Weaknesses
- −The company has delivered a poor sales growth of 10.5% over past five years.
- −Promoter holding is low: 26.4%
- −Tax rate seems low
- −Earnings include an other income of Rs.191 Cr.
- −Promoter holding has decreased over last 3 years: -25.2%
Shareholding Pattern
Promoters26.38%
FIIs17.22%
DIIs10.2%
Public46.2%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.5% | 51.47%▼0.0 | 51.45%▼0.0 | 51.31%▼0.1 | 26.42%▼24.9 | 26.4%▼0.0 | 26.38%▼0.0 | 26.38% |
| FIIs | 11.35% | 13.43%▲2.1 | 14.94%▲1.5 | 16.51%▲1.6 | 17.23%▲0.7 | 17.43%▲0.2 | 17.57%▲0.1 | 17.22%▼0.4 |
| DIIs | 11.55% | 11.2%▼0.4 | 11.58%▲0.4 | 10.98%▼0.6 | 10.44%▼0.5 | 9.97%▼0.5 | 9.55%▼0.4 | 10.2%▲0.6 |
| Public | 25.58% | 23.89%▼1.7 | 22.03%▼1.9 | 21.2%▼0.8 | 45.9%▲24.7 | 46.21%▲0.3 | 46.49%▲0.3 | 46.2%▼0.3 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 322 | 314 | 330 | 358 | 319 | 317 | 334 | 349 | 347 | 353 |
| Expenses | 258 | 259 | 271 | 294 | 264 | 258 | 272 | 283 | 282 | 293 |
| Operating Profit | 64 | 56 | 59 | 64 | 54 | 59 | 62 | 66 | 64 | 60 |
| OPM % | 20% | 18% | 18% | 18% | 17% | 19% | 19% | 19% | 19% | 17% |
| Net Profit | 50 | 58 | 39 | 64 | 44 | 64 | 32 | 94 | 126 | 43 |
| EPS ₹ | 1.56 | 1.82 | 1.21 | 1.99 | 1.38 | 1.99 | 0.99 | 2.94 | 3.95 | 1.34 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹1,383Cr, up 4.5% YoY. OPM at 18%.
Debt Position
Borrowings at ₹523Cr. Debt-to-equity ratio: 0.47x. Healthy balance sheet.
Capex Cycle
CWIP at ₹26Cr (3% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 10.2% (-5.65pp change). FIIs: 17.22% (+5.00pp change). Promoters hold 26.38%.
Margin & Efficiency
ROCE improving from 12% (Mar 2015) to 23% (Mar 2026). Working capital days: 30.
Valuation
PE 21.6x with 22.9% ROCE. Price is 480% above book value of ₹36.9. Dividend yield: 2.37%.
Recent Announcements
- Newspaper Publication With Respect To The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended On March 31, 2026 2d
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 14 May - Audio recording of 14 May 2026 investor call on audited FY26 results made available online.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 14 May - EPL reported Q4 FY26 revenue up 17.6% to ₹13,005mn; FY26 revenue rose 13% to ₹47,631mn.
- Appointment Of Cost Auditors And Internal Auditor Of The Company 14 May - Board approved re-appointment of Jitendrakumar & Associates as cost auditors and appointed Vinay Thakur as internal auditor on May 14, 2026.
- Announcement under Regulation 30 (LODR)-Investor Presentation 14 May - Investor Presentation on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31, 2026, is …
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse